Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects

Clinical Drug Investigation

Volumn 26, Issue 1, 2006, Pages 29-34

  Kreutz, Reinhold ^a   Bolbrinker, Juliane ^a   Huber, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG TOLERANCE; EVALUATION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PARAMETER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AREA UNDER CURVE; CROSS-OVER STUDIES; DIURETICS; DRUG INTERACTIONS; HUMANS; HYDROCHLOROTHIAZIDE; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 30744444170     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626010-00004     Document Type: Article

References (16)

1. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103 (6): 904-12
2. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351 (9117): 1693-7
3. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345-53
4. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17 (6): 425-32
5. Puchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997; 15 (12 Pt 2): 1809-12
6. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihyperten-sive agents: olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001 19 Suppl 1: S49-56
7. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87 (8A): 37C-43C
8. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3 (5): 283-91, 318
9. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23 (7): 419-30
10. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252-9
11. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-53
12. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42 (6): 1206-52
13. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15 (6): 657-80
14. Chow S, Liu J. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker, 1992: 113-7
15. Jonkman JH, van Lier JJ, van Heiningen PN, et al. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens 1997; 11 Suppl. 2: S31-5
16. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13 (4 Pt 1): 418-26